Comparing the current results to its competitors, Aclarion Inc reported Revenue increase in the 1 quarter 2026 by 11.32 % year on year. The sales growth was above Aclarion Inc 's competitors' average revenue growth of 7.28 %, achieved in the same quarter.
Aclarion Inc , slower than the average decrease reported by the company's competitors of -30.92 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -30.92 %
Aclarion Inc 's Comment on Competition and Industry Peers
The company's primary competitors in the discogenic low back pain diagnostic market include established diagnostic standards such as X-ray, lumbar MRI, and provocation discography (PD). These diagnostic platforms are predominantly offered by large, well-capitalized companies with significant market share, extensive resources, established sales and marketing programs, recognized brand names, long operating histories, and established customer relationships. Competitors may also develop or acquire patents or other rights that could restrict the company's ability to compete, potentially leading to price reductions, decreased margins, and loss of market share. The company asserts that its NOCISCAN product suite offers advantages over standard lumbar MRI, which primarily detects structural defects, degeneration, and hydration but has limited correlation with identifying the condition.
Company's competitiveness improved within Overall company, with revenue growth of 11.32 % and its market share increased to approx. 0 %. << More on ACON Market Share.
*Market share is calculated based on total revenue.
September 10, 2024
In the realm of contemporary medical innovation, Aclarion Inc. has recently unfolded a pivotal chapter within its ambitious LIFEHAB trial. The company has taken significant strides by successfully conducting its inaugural Nociscan examinations, aimed at elucidating the intricate relationship between biomarkers located within the disks of the lumbar spine and the corresponding responses to medical treatments. This endeavor positions Aclarion at the vanguard of diagnostic advancements in the field of spinal care, particularly in an age where biomolecular investigations are at the forefront of therapeutic efficacy.This noteworthy undertaking transpires within a broader context of market vicissitude, where Aclar...
September 5, 2024
In the grand theatre of medical progress, where the eldritch shadows of affliction linger, a beacon of hope emerges with the advent of Aclarion Inc.’s strategic partnership with esteemed practitioner, Dr. Justin Kubeck, M.D. of Ocean Pain and Spine, Toms River, New Jersey. This collaboration heralds the introduction of Nociscan, an artificial intelligence technology poised to revolutionize the landscape of personal injury and workers compensation, particularly within the suffering subset of our populace afflicted with low back pain.In a period marked by both triumph and tribulation, Aclarion Inc. despite reporting a cumulative net loss amounting to a staggering six million dollars during the twelvemonth c...
August 14, 2024
In a significant leap for healthcare technology in Michigan, Aclarion, a company focused on advanced diagnostic solutions, has secured its first commercial agreement in the state to deploy its innovative Nociscan technology. This milestone marks a critical advancement in the realm of medical imaging and diagnostics, potentially transforming patient care across the region. Overview of Nociscan The Nociscan is a cutting-edge diagnostic tool designed to enhance the accuracy of imaging by addressing specific musculoskeletal conditions. This technology utilizes patented algorithms combined with neural networks to provide what the company describes as detailed insights into painful areas within the body. By identi...
American Shared Hospital Services Share Performance
+4.38%
This Quarter
American Shared Hospital Services
Profile
American Shared Hospital Services (ASHS) operates a unique business model by providing state-of-the-art medical equipment on a shared basis to hospitals and medical centers across the United States. They establish partnerships with healthcare providers, offering the latest technology for radiation therapy, radiosurgery, and nuclear medicine without the need for significant capital investments. By leveraging their expertise and established relationships in the healthcare industry, ASHS delivers cost-effective solutions that benefit both patients and healthcare facilities alike.
Nano X Imaging Ltd is a medical imaging technology company that aims to revolutionize the field by developing and commercializing a novel digital X-ray system. Their business model involves building partnerships with healthcare providers, imaging equipment manufacturers, and distributors to bring their innovative technology to market, providing cost-effective and accessible diagnostic solutions globally. By delivering high-quality imaging at a fraction of the cost of traditional systems, Nano X Imaging aims to improve healthcare outcomes and increase patient access to effective diagnostics.
Butterfly Network Inc's business model involves developing and providing handheld ultrasound devices that are portable, affordable, and user-friendly. Their products aim to revolutionize medical imaging and provide accessible healthcare solutions.
Check Cap Ltd is a medical technology company that develops and commercializes an ingestible imaging capsule that allows for the detection and monitoring of colorectal polyps. Their business model revolves around manufacturing and selling this capsule device while also providing associated services and support to healthcare professionals and patients.
GE Healthcare Technologies Inc's business model is focused on providing innovative medical devices, healthcare information technology, and healthcare services to improve patient care and outcomes. The company offers a wide range of products and solutions in areas such as medical imaging, patient monitoring, diagnostics, and healthcare IT. They also collaborate with healthcare providers and partners to offer integrated solutions and support throughout the entire healthcare ecosystem.
Sources:
Aclarion Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aclarion Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
